<DOC>
<DOCNO>EP-0656889</DOCNO> 
<TEXT>
<INVENTION-TITLE>
9-CHLOROPROSTAGLANDIN ESTERS AND AMIDES AND THEIR USE IN THE PREPARATION OF DRUGS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P700	A61P700	A61K4748	A61P2706	A61P4300	A61P2700	A61K4748	A61P4300	A61K315575	A61K31557	C07C40500	A61K31557	C07C40500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	A61P	A61P	A61P	A61K	A61P	A61K	A61K	C07C	A61K	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P7	A61P7	A61K47	A61P27	A61P43	A61P27	A61K47	A61P43	A61K31	A61K31	C07C405	A61K31	C07C405	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention concerns 9-chloroprostaglandin esters and amides of general formula (I), methods of preparing them and their use as drugs.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SCHERING AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SCHERING AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUCHMANN BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
MCDONALD FIONA
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
THIERAUCH KARL-HEINZ
</INVENTOR-NAME>
<INVENTOR-NAME>
BUCHMANN, BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT, ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
MCDONALD, FIONA
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA, WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
THIERAUCH, KARL-HEINZ
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Pharmaceutical preparations comprising esters or amides of 9-chloroprostaglandins
of formula (I)



in which

X
represents oxygen or CH
2
, and
R
1
represents COOR
2
, wherein R
2
 is an optionally substituted C
1
-C
10
alkyi, C
3
-C
10
-cycloalkyl,
C
6
-C
10
aryl or C
6
-C
10
ar(C
1
-C
4
)alkyl radical,
or CONHR
3
, wherein R
3
 is an optionally substituted C
1
-C
10
alkyl radical,

for treating raised intraocular pressure.
Pharmaceutical preparations comprising 9-chloroprostaglandin esters or amides
of the general formula (I)



in which

X
represents oxygen or CH
2
, and
R
1
represents COOR
2
, wherein R
2
 is an optionally substituted phenacyl radical,
or CONHR
3
, wherein R
3
 is an optionally substituted C
1
-C
10
alkyl radical,
 
for treating raised intraocular pressure and for cytoprotection, for healing ulcers, for

inhibiting the secretion of gastric acid, for luteolysis, for reducing blood pressure or
for inhibiting platelet aggregation.
Use of 9-chloroprostaglandin derivatives according to claim 1 and 2 in the preparation
of medicaments for treating raised intraocular pressure.
9-Chloroprostaglandin esters and amides of the general formula (I)


in which

X
represents oxygen or CH
2
, and
R
1
represents COOR
2
, wherein R
2
 is an optionally substituted phenacyl radical,
or CONHR
3
, wherein R
3
 is an optionally substituted C
1
-C
10
alkyl radical.
Esters of 9-chloroprostaglandins of the general formula (I)


in which

X
represents oxygen or CH
2
, and
R
1
represents COOR
2
, wherein R
2
 is an optionally substituted C
2
-C
3
alkyl, cyclopentyl,
cyclohexyl, phenyl or benzyl radical,

and their cyclodextrin clathrates. 
Process for the preparation of 9-chloroprostaglandin esters and amides of
formula (I), characterised in that a compound of formula (II)



in which X is as defined above,

is reacted, with the addition of a suitable base, with an optionally substituted haloacetophenone
derivative of the general formula (III)



in which

R
4
represents C
1
-C
4
alkyl, chlorine, bromine or iodine, and
Hal
represents chlorine or bromine,

in a polar solvent to form compounds of the general formula (la)


or

an alkyl ester of the general formula (Ib) 


in which X is as defined above,

is reacted, without a solvent, with an amine of the general formula (IV)

H
2
N-R
3

to form compounds of the general formula (Ic)

Process for the preparation of esters of 9-chloroprostaglandins of formula (I) in
which


X
represents oxygen or CH
2
, and
R
1
represents COOR
2
, wherein R
2
 is an optionally substituted C
2
-C
3
alkyl, cyclopentyl,
cyclohexyl, phenyl or benzyl radical,

characterised in that, in a manner known 
per se,
 a compound of formula (II)

 
in which X is as defined above,

is either

A. reacted in the presence of a suitable base in a polar solvent with a compound of
the general formula (III')


Hal-R
2

in which R
2
 is as defined above but is not phenyl and Hal represents chlorine,
bromine or iodine, at temperatures of from -80째C to 100째C, and the resulting ester is

isolated, or reacted in the presence of a suitable base in a polar solvent after activation
with a carbodiimide such as, for example, dicyclohexylcarbodiimide with phenol

at temperatures of from -30째C to 50째C, and the resulting ester is isolated.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-16, 17,18,19,20-pentanor-5,13-prostadienoic
acid phenacyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-16, 17,18,19,20-pentanor-5,13-prostadienoicacid
(3-hydroxypropyl)amide.
(5Z,13E)-(9R,11R,15S)-9-Chloro-3-oxa-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoicacid
phenacyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-3-oxa-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic

acid (3-hydroxypropyl)amide.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic
acid methyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-16, 17,18,19,20-pentanor-5,
13-prostadienoicacid ethyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic
acid isopropyl ester. 
(5Z,13E)-(9R,11R,15S)-9-Chloro-3-oxa-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic
acid methyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-3-oxa-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic
acid ethyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-3-oxa-15-cyclohexyl-11,15-dihydroxy-16,17,18,19,20-pentanor-5,13-prostadienoic
acid isopropyl ester.
(5Z,13E)-(9R,11R,15S)-9-Chloro-15-cyclohexyl-11,15-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5,13-prostadienoic
acid tert.-butyl ester.
Medicament comprising one or more compounds of claims 4 and 5 and customary
excipients and carriers.
</CLAIMS>
</TEXT>
</DOC>
